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Abstract
Background
In real life, outcomes in wet age related macular degeneration (W-AMD) continue to fall
behind the results from randomized controlled trials. The aim of this trial was to assess if
outcomes can be improved by an intervention in healthcare organization following recom-
mendations of the Chronic Care Model (CCM).
Methods
Multi-centered randomized controlled clinical trial. The multifaceted intervention consisted
in reorganization of care (delivery by trained chronic care coaches, using reminder systems,
performing structured follow-up, empowering patients in self-monitoring and giving deci-
sion-support). In the control usual care was continued. Main outcome measures were
changes in ETDRS visual acuity, optical coherence tomography (OCT) macular retinal
thickness and quality of life (NEI VFQ-25 questionnaire).
Results
169 consecutive patients in Swiss ophthalmology centers were included. Mean ETDRS
baseline visual acuity of eyes with W-AMD was 57.8 (± 18.7). After 12 months, the
between-group difference in mean change of ETDRS visual acuity was -4.8 (95%CI: -10.8
to +1.2, p = 0.15); difference in mean change of OCT was +14.0 (95% CI -39.6 to 67.6, p =
0.60); difference in mean change of NEI VFQ-25 composite score mean change was +2.1
(95%CI: -1.3 to +5.5, p = 0.19).
Conclusions
The intervention aiming at improving chronic care was not associated with favorable out-
comes within 12 months. Other approaches need to be tested to close the evidence-perfor-
mance gap in W-AMD.
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Introduction
Wet age related macular degeneration (W-AMD) is a chronic and progressive disease leading
to loss of visual acuity and is already the most common cause for acquired blindness in devel-
oped countries.[1, 2] Choroidal neovascularizations are the pathological process leading to
visual loss in W-AMD. Since the development of monoclonal antibodies and inhibitors target-
ing the vascular endothelial growth factor A (Ranibizumab, Bevacizumab and Aflibercept),
effective treatments applied by intravitreal injections are available.[3] The MARINA,
ANCHOR and the VIEW1 and 2 studies are regarded as the cornerstone studies in the use the
Anti VEGF-A agents in W-AMD and demonstrated that the decline of visual acuity caused by
W-AMD can not only be delayed or halted but even reversed and clinically relevant gains of
visual acuity can be achieved.[4–6]
Interestingly, in real life outcomes are found to be less favorable than in clinical trials.[7]
The most plausible explanation for this finding an evidence-performance gap (e.g. patients in
real life do not receive care as provided in interventions within clinical trials). In real life,
healthcare for AMD is challenging, not only because of the considerable treatment costs and
because of the controversies about the different propagated treatment-regimes but also because
of disease inherent reasons. The natural course of W-AMD is insidious because active and
inactive stages alternate unpredictably and with considerable variability between patients. Is
has been shown that treatment discontinuation because of disease inactivity is associated with
considerable visual loss within only 4 years.[8] The importance of successful clinical follow-up
is undoubted, independently whether a fixed dosage regime as labelled is followed or whether
W-AMD is managed with the popular “pro re nata” or the “treat and extend” protocols.[9, 10]
Furthermore, the time from symptom begin to treatment initiation is paramount. Treatment
effects from anti VEGF-A drugs are only prominent when treatment is initiated within the first
month of symptom onset.[11] Congruently, guidelines not only recommend regular follow-up
visits but also encourage self-monitoring by patients i.e. by applying self-administered Amsler
tests.[12]
Successful follow-up and patient empowerment e.g. in self-monitoring are recognized in
treatment of AMD as they are in most classic chronic conditions such as hypertension, diabetes
and many more. However, there are more relevant aspects of chronic illness care and all these
have been encompassed comprehensively by Wagner and colleagues within the “Chronic Care
Model” (CCM). The CCM is a generic, evidence-based template designed as a conceptual
framework integrating the relevant elements of chronic care that have to be considered to
achieve best possible outcomes in chronic conditions.[13] In addition to follow-up manage-
ment and patient-empowerment, the CCM aims at mobilization of community resources, tai-
loring of the delivery system design, enhance decision-support and integrate clinical
information systems. Interventions targeting at least two of these elements have consistently
shown to improve outcomes in several typical chronic conditions such as diabetes, chronic
obstructive pulmonary disease (COPD), asthma or depression as systematic reviews confirm.
[14–17]
The CCM has widespread acceptance and is even promoted by the WHO as the ideal tem-
plate to provide care in chronic conditions.[18] The CCM can be applied also in W-AMD and
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elements such as empowerment of patients in self-monitoring for example have already shown
to enhance specific outcomes in W-AMD.[19] The CCM has however, not yet been tested in a
broader implementation as a whole framework in care for W-AMD regarding patient-relevant
outcomes.
We hypothesized that the implementation of the CCMmight fill the observed evidence-per-
formance gap and improve outcomes in W-AMD. We therefore undertook a multicenter ran-
domized clinical trial aiming to improve visual function (primary objective) and quality of live
(secondary objective) by implementing core elements of the CCM in care for W-AMD.
Methods
Study design
The CHARMED study was a multicenter, open label, randomized, controlled clinical trial that
was conducted in 12 different Swiss ophthalmology clinics. The aim of the CHARMED study
was to assess the effects of an implementation of the CCM in care for patients with W-AMD.
The methods of the study have been reported in detail and are summarized below.[20]
Recruiting of consecutive patients in the study centers started in April 2011 and ended in
January 2013. Randomization was performed on the patient level utilizing block randomization
stratified per study center, block size was 4 and allocation ratio was 1:1. The randomization list
was generated using STATA statistical software version 11, the list was stored centrally at the
Institute for Primary Care. Study centers had no access to this list and had to inquire the alloca-
tion of each individual patient by telephone call immediately after patient inclusion.
Eligible subjects were male or female patients, aged 50 years or older, with W-AMD, who
were eligible for therapy with antiangiogenic drugs, had a best corrected visual acuity of at least
20 letters assessed with the Early Treatment Diabetic Retinopathy (ETDRS) chart and provided
written informed consent in study participation. In cases where both eyes were affected by
W-AMD, both eyes were included and followed in the study.
Exclusion criteria were serious general or psychological illness (advanced malignant dis-
eases, severe depressive disorders or dementia) and insufficient German or French language
skills (for completing the self-administered questionnaires). We intended to include treatment-
naïve patients, thus patients with any former invasive medical treatment for W-AMD were
also excluded.
Data was collected at inclusion (baseline, T0), at 6 months follow-up (T1) and at 12 months
follow-up (T2). Clinical measurements (OCT and ETDRS visual acuity) were conducted by
ophthalmologists who received instructions in standardized measurements using the ETDRS
chart, structured interviews were conducted by trained practice assistants in a face-to-face or
telephone setting and self-administered questionnaires were completed by the patients.
Interventions
In the control group, there was no study specific intervention. The study sites were instructed
to deliver care as usual and to avoid introduction of intervention-specific components.
In the intervention group, established evidence based core elements of the CCM were intro-
duced. Delivery of these CCM elements was organized as follows: In every study site a practice
assistant was assigned to be the “Chronic Care Coach” (CCC). The CCCs attended a one-day
training course comprising the instructions and materials to utilize as means to introduce the
CCM core elements. In specific the following elements were introduced:
Organization of health care delivery system. In the intervention group, care was
organized by the CCCs. This included planning and arranging the contact between patients
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and physicians and a monthly structured follow-up call with the patients. The CCCs used,
delivered or implemented the diverse elements or instruments of the multifaceted
intervention.
Self-management support. Patients in the intervention group were individually
instructed in self-management by the CCCs. These private teaching sessions comprised the
self-assessment of the Amsler-test, which was to be performed by the patient weekly with
both eyes separately. Furthermore, patients in the intervention group received an action plan
that helped them dealing with symptoms, estimate their severity and how to react in the case
of deterioration. The action plan also contained an overview of the planned visits and the
contact information of the CCC. Additionally, to enhance self-management support,
patients in the intervention group were invited to peer-group meetings with experienced
patients suffering fromW-AMD at least twice during the 12 month intervention period.
Originally we also planned to introduce self-measuring on the patient level utilizing an app
designed to monitor visual acuity on a mobile device, this component, however, was aban-
doned as the visual acuity test on the app failed to demonstrate validity according to the
manufacturer.
Decision support. Patients in the intervention group were provided with leaflets by the
CCCs containing “Don’t worry” and “Call immediately” items including a checklist for antibi-
otic eye drops and all important contact addresses.
Clinical information systems. A computer system designed to remind and structure the
follow-up of patients in the intervention group was used by the CCCs. The system targeted at
achieving three monthly injections at study begin by promptly fixing these appointments at
treatment start, and aimed at successful monthly visits thereafter. The monthly phone calls
were also reminded and managed with this computer system.
Outcome measures
Measurements were performed at baseline (T0), at 6 months (T1) and at 12 months (T2). The
points in time where the individual outcome measurements were performed are reported
below:
Primary outcome. The primary outcome measure was the best corrected visual acuity
measured with the ETDRS chart in sitting position from an initial test distance of 4 meters at
T0, T1 and T2. The primary outcome was the mean change in the ETDRS after 12 months. A
change of 5 letters was regarded as minimal clinically relevant change. In order to enhance
standardization of this measurement an initial teaching visit and at least one outreach visit at
each study center was performed by a study coordinator. Standardized ETDRS charts were
provided.
Secondary outcomes. 1) The physiological outcome was assessed by optical coherence
tomography (OCT) of the central retinal thickness at T0, T1 and T2. 2) The disease-specific
quality of life assessed with the National Eye Institute Visual Function Questionnaire-25 (NEI
VFQ-25).[21] The NEI VFQ-25 was performed at T0, T1 and T2 by face-to-face or telephone
interview. 3) Health service utilization was assessed by self-administered questionnaire (count-
ing the number of visits with the ophthalmologists, with the family physician and stays in hos-
pitals) at T0 and T2. 4) The patient perceived accordance of care to the CCM was measured by
the self-administered Patient Assessment of Chronic Illness Care (PACIC) questionnaire at T0
and T2.[22] 5) The provider perspective on the accordance of care to the CCM was assessed
using the Assessment of Chronic Illness Care (ACIC) questionnaire which was to be completed
in collaboration by the clinic staff at the beginning of recruitment and after follow-up was com-
pleted.[23]
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Sample Size
According to literature, we assumed a mean EDTRS visual acuity of 48 letters and a standard
deviation (SD) of 15 letters at baseline.[5, 24, 25] Assuming a clinically relevant between-group
difference of 5 letters on the ETDRS chart, we needed to include 282 patients to achieve a
power of 80% and a significance level of 5%. The CHARMED–Study-Group, however, decided
to stop recruitment after 169 patients, because the recruitment proceeded much slower than
expected.
Trial registration and ethics statement
The trial has been registered at Current Controlled Trials (ISRCTN32507927). Ethics commit-
tee approval was obtained (Ethics Committee of the Canton of Zurich, KEK-ZH-NR: 2010-
04391/1). Informed consent was obtained from subjects prior to inclusion, the study was per-
formed adhering to the tenets of the Declaration of Helsinki and according to Good Clinical
Practice Guidelines.
Statistical Analysis
Continuous variables are presented as means and standard deviations (SD) or as medians and
interquartile ranges (IQR) as appropriate. Categorical data is presented as counts and propor-
tions. Analysis was conducted according to the intention to treat principle. We compared
between-group differences using T-test or Wilcoxon rank sum test for continuous data and
using Χ2-statistics or Fisher’s exact test for categorical data as appropriate and report two-sided
P values. We report mean changes and respective 95% confidence intervals (CIs) of outcome
variables compared to baseline. Missing primary outcome data was inserted with the mean of
the control group for analysis of the primary outcome in order to prevent bias from selective
drop-out, as predefined in the study protocol. For the construction of the PACIC summary
score one missing item out of 20 was allowed, other missing data was left as missing. When
two eyes were affected by W-AMD in the same patient, every included eye in the study was
analyzed separately. A two-sided alpha of 0.05 was set as level of significance for all compari-
sons. Statistical analyses were calculated using R Statistics version 3.1.0.
Results
Patient characteristics
Of 169 recruited patients, 84 were randomized to the intervention group, 85 to the control
group. Eight patients in the intervention group and 13 patients in the control group had both
eyes affected with W-AMD, thus, the intervention group comprised 92 eyes, the control group
98 eyes under the respective treatment protocols. The mean age of the patients was 76.7 (±8.0)
years, 107 (63.3%) were female. 111 (65.7%) of the patients suffered from at least one other
additional chronic condition. A detailed description of the study samples baseline characteris-
tics and the recruiting study sites has been published and is openly available.[26] During the
12 month follow-up period, the drop-out rate was similar in both groups (17 dropouts
[20.2%] in the intervention group and 12 [14.1%] in the control group), reasons for drop out
did not differ significantly (Fig 1, Fisher’s exact test: p = 0.68). Table 1 displays the baseline
characteristics, the groups appear to be well matched. Remarkably, patients in the control
group, per chance, had a 4 letters lower median ETDRS score at baseline (Wilcoxon rank sum
test: p = 0.16).
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Primary outcome
After 6 months, the mean change of ETDRS visual acuity in the intervention group was +0.3
(95% CI: -3.4 to +4.0) letters, in the control group +2.7 (95%CI: -1.0 to +6.4) letters, the
between-group difference in mean change was -2.4 (95%CI: -7.6 to +2.8, T-test for equal mean
differences: p = 0.36). After 12 months, the mean change of ETDRS visual acuity in the inter-
vention group was -0.3 (95%CI: -4.4 to +3.8) letters, in the control group +4.5 (95%CI: +0.1 to
+8.9) letters, the between-group difference in mean change was -4.8 (95%CI: -10.8 to +1.2, T-
test for equal mean differences: p = 0.15). The targeted superiority of +5 ETDRS letter in favor
Fig 1. Flow Chart of the study. Fig 1 shows the flow chart of the study. The number of patients as well as the number of eyes with W-AMD is shown through
the process.
doi:10.1371/journal.pone.0143085.g001
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of the intervention group remained unreached. The trend of mean ETDRS visual acuity over
time is plotted (Fig 2).
Secondary outcomes
OCT retinal thickness: After 6 and 12 months there were significant improvements of OCT ret-
inal thickness within both groups (Table 2), the between-group differences in mean change
were, however, was not statistically significant: at 6 months +21.0 (95%CI: -30.4 to +72.3,
p = 0.42) and at 12 months +14.0 (95%CI: -39.6 to +67.6, p = 0.60). The trend of retinal thick-
ness over time is plotted (Fig 3).
NEI VFQ-25 summary score (reflecting the disease-specific quality of life): After 6 months,
there was no significant change in NEI VFQ-25 summary score in either group, after 12
months the score improved significantly in the intervention group (Table 2). The between-
group differences in mean change were, however, not statistically significant: at 6 months -0.3
(95%CI: -3.9 to +3.4, p = 0.87) and at 12 months +2.1 (95%CI:-1.3 to 5.5, p = 0.18). The trend
of the NEI VFQ-25 summary score over time is plotted (Fig 4).
PACIC summary score (patient perceived accordance of care to the CCM): After 12
months, the PACIC summary score improved significantly in both groups (Table 2), however,
without any between-group difference: 0.0 (95%CI: -0.6 to +0.6, p = 0.99).
Table 1. Baseline characteristics of study population.
Variable (description method) Intervention n = 84 Control n = 85
Age in years (mean ±sd) 76.5 ± 8.2 76.9 ± 8.2
Female sex (n and %) 58 69.0% 49 57.6%
Education years (mean ±sd) 11.3 ± 2.8 12.6 ± 2.8*
Positive family history for wet AMD (n and %) 12 14.3% 16 18.8%
Diabetes (n and %) 8 9.5% 6 7.1%
Arterial hypertension (n and %) 42 50.0% 50 58.8%
Coronary heart disease(n and %) 12 14.3% 17 20.0%
Heart failure (n and %) 3 3.6% 5 5.9%
Cerebrovascular disease (n and %) 8 9.5% 6 7.1%
Chronic obstructive pulmonary disease (n and %) 7 8.3% 9 10.6%
Malignant disease (n and %) 5 6.0% 6 7.1%
Current or former smoker (n and %) 33 39.3% 42 49.4%
PHQ9 summary score1 (median and IQR) 2 1 to 4 2 1 to 4
ETDRS visual acuity of eyes with wet AMD2 (median and IQR) 62 47 to 73 58 43 to 73
OCT retinal thickness (median and IQR) 364 279 to 415 331 270 to 454
NEI-VFQ253 composite score (median and IQR) 85 75 to 93 88 80 to 93
PACIC4 summary score (median and IQR) 2.4 1.8 to 3.2 2.4 1.7 to 3.2
1The PHQ9 is a measure of depression and its severity (range 0 to 27) as a self-administered questionnaire, values between 0 and 4 are interpreted as
minimal depressive symptoms not requiring speciﬁc treatment
2The total n for this variable is the number of eyes, i.e. 92 in the intervention group and 98 in the control group
3The VFQ-25 composite score ranges from 0 to 100 and is a measure of visual function speciﬁc quality of life, 0 represents the lowest quality of life, 100
the highest quality of life.
4The PACIC summary score ranges from 1 to 5 and is a measure of the chronic illness care concordance to the chronic care model from the patient’s
perspective, 1 represents the lowest concordance, 5 represents the highest concordance.
*Welch Two Sample t-test, p = <0.05
doi:10.1371/journal.pone.0143085.t001
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After 12 months, the median number of ophthalmologist visits because of W-AMD in the
intervention group was 12 (IQR: 9 to 12) and in the control group also 12 (IQR: 7 to 13, Wil-
coxon rank sum test: p = 0.523). There was clearly greater variability in follow-up in the control
group (Fig 5) arguing that care in the intervention group was more structured, however, with-
out resulting in improved outcomes as demonstrated above. Concerning family physician
Fig 2. ETDRS visual acuity. Fig 2 shows outcome data for the ETDRS visual acuity through the study
period. Point estimates are mean numbers of correctly identified letters, error bars represent 95% confidence
intervals. The red line is for the intervention group, the black line is for the control group.
doi:10.1371/journal.pone.0143085.g002
Table 2. Within groupmean changes and 95% confidence intervals in secondary outcomes.
Variable (description method) Follow-up Intervention group Control group
OCT retinal thickness (μm) 6 months -62.0 (95%CI: -96.3 to -27.7) -82.9 (95%CI: -121.7 to -44.2)
OCT retinal thickness (μm) 12 months -77.7 (95%CI: -119. to -35.6) -91.7 (95%CI: -125.5 to -57.8)
NEI-VFQ251 (composite score) 6 months +2.1 (95%CI: -0.4 to +4.6) +2.4 (95%CI: -0.3 to +5.1)
NEI-VFQ251 (composite score) 12 months +3.4 (95%CI: +1.1 to +5.7) +1.3 (95%CI: -1.2 to +3.8)
PACIC2 (summary score) 12 months +0.6 (95%CI: +0.1 to +1.0) +0.6 (95%CI: +0.2 to +1.0)
1The VFQ-25 composite score ranges from 0 to 100 and is a measure of visual function speciﬁc quality of life, 0 represents the lowest quality of life, 100
the highest quality of life.
2The PACIC summary score ranges from 1 to 5 and is a measure of the chronic illness care concordance to the chronic care model from the patient’s
perspective, 1 represents the lowest concordance, 5 represents the highest concordance.
doi:10.1371/journal.pone.0143085.t002
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consultations and hospitalizations no significant differences between the study groups
appeared (data not shown).
The mean ACIC score which measures the study site perceived accordance of care to the
CCM at baseline was 5.6 (±2.18). After 12 months the trend went upwards, the mean change,
however, was not statistically significant: +1.2 (95%CI: -0.6 to +2.9, paired Wilcoxon rank sum
test: p = 0.09).
Discussion
In this randomized controlled study we tested the effect of core elements of the CCM on rele-
vant outcomes in W-AMD. We found no significant effect of the CCM intervention for any of
the assessed outcomes. Moreover, the between-group difference in mean change of the visual
acuity failed not only to achieve statistical significance but the targeted superiority of +5
ETDRS letter was not even reached by the upper border of the 95% confidence interval. In view
of the distribution of these results, we see our hypothesis of superiority of the CCM strongly
antagonized even without reaching the intended sample size in this trial. We must therefore
acknowledge that the implementation of core elements of the CCM was ineffective to improve
the most important outcomes in AMD.
Beneficial results of the CCM found in many other chronic conditions were not reproduc-
ible in AMD. For this finding, several explanations are possible because W-AMDmight differ
importantly from classic chronic conditions. Regarding for instance the natural course of
Fig 3. Optical coherence tomography retinal thickness. Fig 3 shows the optical coherence tomography
(OCT) macular retinal thickness in micrometers. Point estimates are mean values, error bars represent 95%
confidence intervals. The red line is for the intervention group, the black line is for the control group.
doi:10.1371/journal.pone.0143085.g003
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W-AMD, phases of disease activity and inactivity alternate and so far, no modifiable factors
that could be targeted by chronic care interventions are known. This is very much in contrast
to most classical chronic conditions, where modifiable risk factors are very well established and
targeting those is clearly effective. In W-AMD, our intervention focused mainly on the early
detection of disease activity introducing self-monitoring. Self-monitoring itself has clear advan-
tages in many chronic conditions when an otherwise undetectable measure of disease activity
is monitored (such as blood sugar in diabetes or blood pressure in hypertension). Again gener-
alizability from classic chronic conditions to W-AMDmight be limited because also naïve
patients might detect disease activity with great sensitivity when noticing visual loss, in contrast
to a diabetic for example that very much depends on empowerment in self-monitoring to
detect hyperglycemia. Self-monitoring is already occurring naturally in daily living in AMD,
thus the effects of an additional self-monitoring support might be much smaller than in most
chronic conditions and a simple Amsler Test might not bring decisive advantages. Similarly,
benefits from empowerment of patients with decision aids and action plans might be limited in
AMD. Generally, patients benefit from decision aids or action plans, when a multitude of
options is available within a complex framework where several circumstances need to be con-
sidered. Again, diabetes is a good example for CCM effectiveness: The activated and informed
patient knows how to counteract hyperglycemia following sophisticated action plans covering
physical activity, nutritional changes and even autonomous adaptation of pharmacotherapy. In
W-AMD however, patients noticing a relevant deterioration have very little options: call the
Fig 4. NEI VFQ-25 quality of life. Fig 4 shows the visual function specific quality of life measured by the
NEIVFQ-25 composite score. Point estimates are mean values, error bars represent 95% confidence
intervals. The red line is for the intervention group, the black line is for the control group.
doi:10.1371/journal.pone.0143085.g004
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ophthalmologist. Patients with W-AMD are very well aware of this option and the introduction
of decision aids and action plans might yield only minimal additional benefit.
Interestingly, in our study we found that patients with W-AMD had importantly better
visual functioning at baseline than in previous studies with similar inclusion criteria or real life
observational studies: Whereas we expected to include patients with an average ETDRS visual
acuity around 48 to 55 letters, the patients in our study had a mean ETDRS visual acuity of 58
Fig 5. Clinic visits at the ophthalmologists. Fig 5 are boxplots comparing the intervention versus the
control groups with regard to the number of visits at the ophthalmologist because of W-AMD. The hinges are
the first and third quartile, the horizontal line is the median, the whiskers extend from the hinges to the value
within 1.5 times the IQR.
doi:10.1371/journal.pone.0143085.g005
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letters.[4–7, 24, 25] This finding can be explained by the setting of the study. Most patients
were recruited in urban regions in hospital run ophthalmology clinics. Arguably, these were
patients with a very good access to healthcare in an already comparably wealthy healthcare sys-
tem. These circumstances might have further limited the additional effects of the CCM imple-
mentation of our study because also usual care for those patients was already highly organized
and featured many characteristics of the CCM. This is reflected by the comparably high ACIC
scores we found in the trial and by the non-differing and equally risen PACIC scores of the
study groups.
This study has strengths and limitations. It is the first study evaluating effects of core ele-
ments of the CCM on patients with W-AMD, a disease where treatment protocols are still to
debate and a relevant evidence-performance gap exists. The most important limitation of the
study is that recruitment was more difficult than anticipated and the study was stopped early.
The failure of the CCM implementation was, however, very clear, even if the intended sample
size was not reached. We are confident, that more patients would not have completely reversed
the trend that appeared to be even in favor of the control group. Another limitation was the
open label design of the study, the awareness of allocation in the intervention group, however,
would have introduced bias in favor of the intervention, our opposite finding rather in favor of
the control group is thus added credibility to our rejection of the study hypothesis. However, as
we randomized on the patient level, contamination bias may have occurred: Even if the groups
were managed separately in the study sites and procedures were monitored, some aspects of the
CCMmight unintentionally have influenced the performance in the control group. The most
important aspects of the intervention (structured follow-up phone calls and Amsler test self-
measurement instructions), however, were definitely only accessible for the intervention group.
It is, however, also safe to assume that “usual care” in the control group also featured some form
of structured follow-up in the highly performing Swiss healthcare system. The intervention
might thus not have been strong enough to achieve an important difference in a health system
with an already successful follow-up as reflected by the non-different median number of 12 oph-
thalmologist visits also found in the control group. Possibly a longer follow-up time than 12
months would have been required to show beneficial effects of the CCM implementation. Ulti-
mately, we did not assess the intended treatment protocol of each individual patient (fixed
monthly injections, PRN or treat and extend), nor did we assess the exact number of injections.
In our framework however, these were only the mediators of the outcomes that should have
been enhanced by the CCM implementation. Successful follow-up is crucial under all treatment
protocols and naturally associated with the number of injections. Improving-follow up should
thus improve outcomes regardless of the individual treatment protocol.
Concluding, we must state that our intervention aiming at improving chronic care was not
associated with favorable outcomes within 12 months in W-AMD. Other approaches need to
be tested to close the evidence-performance gap in W-AMD.
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